Mesoblast : Biotech Showcase 2022 Presentation

onlyuse

JANUARYersonal 2022

ASX: MSB; Nasdaq: MESO

mesoblast

Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases

Corporate Presentation

BIOTECH SHOWCASE 2022

only
use	CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results,

levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward- looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this presentation are forward-looking statements. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," and similar expressions or phrases identify ersonalforward-looking statements. We have based these forward-looking statements largely on our current expectations and future events , recent changes in regulatory laws, and financial trends that we believe may affect our fin ncial condition, results of operation, business strategy and financial needs. These statements may relate to, but are not limited to: expectations regarding the safety or efficacy of, or potential applications for, Mesoblast's dult stem cell technologies; expectations regarding the strength of Mesoblast's intellectual property, the timeline for Mesoblast's regulatory approval process, and the scalability and efficiency of manufacturing processes; expectations about Mesoblast's ability to grow its business and statements regarding its relationships with current and potential future business partners and future benefits of those relationships; statements concerning Mesoblast's share price or potential market capitalization; and statements concerning Mesoblast's capital requirements and ability to raise future capital, among others. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this presentation t gether with our financial statements and the notes related thereto, as well as the risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, include, without limitation: risks inherent in the development and commercialization of p tential products; uncertainty of clinical trial results or regulatory approvals or clearances; government regulation; the need for future capital; dependence upon collaborators; and protection of our intellectual property rights, among others. Accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of

new information, future developments or otherwise.

ersonal use only

Our Mission

Mesoblast is committed to bringing to market innovative cellular medicines to treat serious and life-threatening illnesses

| 3

Platform Technology - Mechanism of Action

Our mesenchymal precursor/stromal cells respond to and are activated by multiple inflammatory cytokines through

surface receptors, resulting in orchestration of an anti-inflammatory cascade

only	IL-10	Breg
use
					TH1	Proliferation
			Mesenchymal
	Proliferation				Cytokine secretion
	Effector	Precursor / Stromal Cell
		Cytotoxicity
	Antibody production
	B cell				TH17
ersonal
Activation	NK	IDO, PGE2
	Cytotoxicity	TGF, M-CSF, CCL2
	Maturation		Treg IL-10
	Activation	Immature DC
	Antigen Presentation	IL-1	M1	M2
			IL-6	IL-10
			TNFα	Polarize
			M1 to M2
Source: Data on file							| 4

JCR Pharmaceuticals Co., Ltd. (JCR), has the right to develop mesenchymal stromal cells (MSCs) in certain fields for the Japanese market, including for the treatment of hematological malignancies, such as Graft vs Host Disease, and for hypoxic ischemic encephalopathy (HIE). Mesoblast has the right to use safety and efficacy data generated by JCR to support its development and commercialization plans for remestemcel-Lin the US and other major healthcare markets, including for GVHD and HIE

Grünenthal has an exclusive license to develop and commercialize rexlemestrocel-Lfor chronic low back pain in Europe and Latin America/Caribbean Tasly Pharmaceuticals has exclusive rights for rexlemestrocel-Lfor the treatment or prevention of chronic heart failure in China

biologic refractory Crohn's & Ulcerative colitis

Inflammatory Bowel Disease (IBD)

focus on ischemics and diabetics

Chronic Heart Failure Reduced Ejection Fraction (HFrEF)3

due to inflammatory degenerative disc disease

Chronic Low Back Pain (CLBP)2

Acute Respiratory Distress Syndrome (ARDS) initially targeting COVID-19

Acute Graft Versus Host Disease (aGVHD)1 steroid-refractory

onlyuse

ersonalThis chart is figurative and does not purport to show individual trial progress within a clinical program 1.

2.

3.

Late-StageClinical Pipeline

THERAPEUTIC AREA

MID-STAGE	LATE STAGE	COMMERCIAL
Phase 2	Phase 3

Remestemcel-LRexlemestrocel-L

| 5